Filana Therapeutics, Inc. Cash Flow-to-Debt Ratio
Filana Therapeutics, Inc. cash flow-to-debt ratio. Filana Therapeutics, Inc. (FLNA) has a Cash Flow-to-Debt Ratio of -0.10x as of June 2026, meaning its operating cash flow of $-3.85 Million could theoretically repay 0% of its total liabilities ($40.29 Million) in one year. See FLNA financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Filana Therapeutics, Inc. (2022–2025)
Cash flow-to-debt ratio of Filana Therapeutics, Inc. from 2022 to 2025. Historical debt coverage capacity for Filana Therapeutics, Inc. across 4 annual periods. Also explore FLNA shareholders equity momentum to track the company's year-over-year net asset growth rate.
Filana Therapeutics, Inc. Cash Flow-to-Debt Ratio by Year (2022–2025)
Filana Therapeutics, Inc. cash flow-to-debt ratio by year from 2022 to 2025. Year-by-year debt coverage analysis for Filana Therapeutics, Inc.. For the full cash flow conversion analysis, see Filana Therapeutics, Inc. cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.73x | $-32.25 Million | $43.95 Million | ▲ +92.6% |
| 2024 | -9.88x | $-116.93 Million | $11.83 Million | ▼ -71.1% |
| 2023 | -5.78x | $-82.03 Million | $14.20 Million | ▲ +45.6% |
| 2022 | -10.63x | $-77.51 Million | $7.29 Million | — |